Opthea to Present at Oppenheimer Healthcare Conference

Core Viewpoint - Opthea Limited is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal diseases, particularly wet age-related macular degeneration (wet AMD) [1][3]. Group 1: Company Overview - Opthea is listed on both ASX and NASDAQ under the ticker OPT [3]. - The company is developing therapies for vision-threatening eye diseases, including wet AMD and diabetic macular edema (DME), which are significant causes of vision loss globally [3]. Group 2: Product Development - Opthea's lead product candidate, sozinibercept, is currently in Phase 3 development and is a first-in-class VEGF-C/D 'trap' inhibitor [4]. - Sozinibercept is being evaluated in combination with standard anti-VEGF-A therapies, aiming to provide superior vision outcomes for wet AMD patients [4]. - This therapy has the potential to be the first new treatment in 20 years that allows wet AMD patients to lead fuller and healthier lives [4]. Group 3: Upcoming Events - Frederic Guerard, the CEO of Opthea, will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 10:00 AM ET [2]. - The presentation will be available via webcast, which can be accessed through the company's website [2].